新冠病毒（COVID-19）对慢性乙型肝炎患者肝功能的影响如何？一则病例及文献复习。
What would be the impact of COVID-19 on liver function of a patient with chronic hepatitis B? About a case and literature review.
机构信息
Faculty of Medicine and Pharmacy of Fez, Sidi Mohamed Ben Abdellah University, Laboratory of Human Pathology, Biomedicine and Environment, Fez, Morocco.
Faculty of Medicine and Pharmacy of Fez, Sidi Mohamed Ben Abdellah University, Hassan II University Hospital Center, Fez, Morocco.
出版信息
Pan Afr Med J. 2021 Mar 1;38:225. doi: 10.11604/pamj.2021.38.225.28123. eCollection 2021.
Liver damage during COVID-19 disease has been described in numerous studies. Its mechanism is poorly understood. It is mainly reserved for severe forms and is manifested by abnormalities of the hepatic assessment and more particularly cytolysis. Particular attention must be paid to patients with chronic liver disease, both in terms of follow-up and treatment. We wanted to know the evolution of COVID-19 and its treatment, on the liver function of a 27-year-old patient followed for chronic non-cirrhotic hepatitis B at the Hassan II University Hospital in Fez. Our patient had stopped the antiviral B treatment and presented COVID-19 infection with minimal to moderate impairment. The initial evaluation showed cytolysis at 4 times upper limit of normal (ULN). Management consisted in the immediate resumption of Tenofovir in combination with hydroxychloroquine (HCQ) and azythromycin with good clinical and biological evolution.
在许多研究中都描述了 COVID-19 疾病期间的肝损伤。其发病机制尚不清楚。它主要保留给严重形式，并表现为肝评估异常，更特别是细胞溶解。必须特别注意患有慢性肝病的患者，无论是在随访还是治疗方面。我们想了解 COVID-19 及其治疗在菲斯哈桑二世大学医院接受慢性非肝硬化乙型肝炎随访的 27 岁患者的肝功能的演变情况。我们的患者已经停止了抗病毒 B 治疗，并出现了 COVID-19 感染，损害程度为轻度至中度。初步评估显示细胞溶解达到正常上限的 4 倍（ULN）。治疗包括立即恢复替诺福韦与羟氯喹（HCQ）和阿奇霉素联合治疗，临床和生物学均有良好的改善。
Zotero 插件